- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03070366
Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC (OMET)
Randomized Phase II Trial Comparing Chemotherapy Combined With Stereotactic Radiotherapy and Stereotactic Radiotherapy Alone, for Treatment of Oligometastases in Squamous Cell Cancers of the Upper Aerodigestive Tract
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with cancers of aerodigestive tract have metastases limited in their evolution and a pauci-metastatic disease. In these cases, systemic therapy is the standard attitude. However, patients often received chemotherapy in their history and response rates are relatively low. The median survival is between 7 and 11 months with secondary effects and degradation of quality of life. It is a palliative treatment. Data on systemic treatment in the context of a micro-metastatic disease are limited. In contrast, stereotactic irradiation in pauci-metastatic context leads to better local control rates and may sustainedly reduce the progression of metastatic disease.
Stereotactic radiotherapy is increasing use in clinical practice for limited metastatic stages (oligo metastatic with 1-3 synchronized metastases). Radiotherapy in this indication has major advantages and a similar efficacy compared with other ablative treatments.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Juliette THARIAT, Pr
- Phone Number: +33 (0)6 45 53 98 01
- Email: jthariat@gmail.com
Study Contact Backup
- Name: Xu Shan SUN, MD
- Phone Number: +33 (0)3 81 98 88 68
- Email: xssun@chbm.fr
Study Locations
-
-
-
Montbéliard, France, 25209
- Hopital Nord Franche Comte
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years
- PS:0-2
- Estimated life expectancy ≥ 6 months
- Histologically confirmed diagnosis of squamous cell carcinoma of the head and neck
- Target metastases can be treated in stereotactic radiotherapy
- 1-3 synchronized metastases with unrestricted anatomic site
- Greater cumulative diameter of synchronous metastases in once organ (liver, lung or brain) ≤ 6 cm with GTV = Clinical Target Volume (CTV)
- Global maximum diameter (GTV) allowed for pulmonary oligometastases (less than 2 cm from the mediastinum), brain, node, is ≤ 3cm
- Implementation of a method for taking into account movements and uncertainties (IGRT) for limiting the margin of CTV to PTV (PTV) so as not to exceed 7 cm large cumulative diameter of PTV
- Performing a positron emission tomography with 18F-2-fluoro-2-deoxy-D-glucose (FDG-PET) 4 weeks before the inclusion
- In case of cerebral metastases, MRI diagnostic is required
- If locoregional disease is treated, controlled and non-progressive for more than three months (+/- 4 weeks) at baseline, synchronized initial tumor is possible
- If metachronous metastases, locoregional disease previously treated should be monitored and considered not progressive for more than three months at baseline
- In case of prior cancer other than HNSCC, complete remission for over 5 years is possible, any biopsy of metastases is left to the appreciation of referring physician
- No chemotherapy or local treatment of metastases in the previous 6 months
- Laboratory tests consistent with the achievement of chemotherapy: Leukocytes> 3,000 / mm3 (including polynuclear> 2000 / mm3) platelets> 150,000 / mm3, serum glutamate oxaloacetate transminase (SGOT), serum glutamate pyruvate transaminase (SGPT), alkaline phosphatase, bilirubin <2.5 upper limit of normal (ULN)
- Affiliation to an health insurance
- Informed Consent Form signed
Exclusion Criteria:
- Concomitant participation in other interventional clinical trial within 4 weeks before inclusion
- Other prior ablative treatment of targets metastases (surgery, radio frequency) in the previous six months
- metachronous primitive tumor (second cancer) uncontrolled.
- contraindication to any systemic therapy (chemotherapy and / or targeted therapy)
- Known hypersensitivity reaction to 5FU, cisplatin, carboplatin, platin or cetuximab
- Active infection (infection requiring IV antibiotics), including active tuberculosis and known and declared human immunodeficiency virus (HIV)
- Other malignancies within 5 years prior to randomization, with the exception of adequately treated basal skin cancer and carcinoma in situ of the cervix
- Individual deprived of liberty by judicial or administrative decision, or under any kind of guardianship
- Pregnant or breast feeding women. Every woman who has childbearing potential, must have a negative pregnancy test (serum or urine) within 14 days previous treatment. Patients (men or women) must use a reliable method of contraception throughout treatment and for at least 6 months after discontinuation of chemotherapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Chemotherapy combined with stereotactic radiotherapy (RT)
Chemotherapy is based on patient Performance Status (PS) and comorbidities:
Cycle 1 of systemic treatment will be administered before the start of the stereotactic RT. Then, following cycles will be performed after the end of stereotactic irradiation. Cetuximab maintenance: 250 mg/m² iv weekly. It will be given only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until progression or unacceptable toxicity. |
Stereotactic radiotherapy
|
Experimental: stereotactic radiotherapy
Splitting will be based on the tumor diameter, and proximity of organs at risk which constitutes any limiting toxicities.
It will be 3 or 5 fractions based on the recommendations (CARO-Stereotactic Body Radiation Therapy (SBRT) 2012) and for the purpose of harmonization practices.
The prescription dose is 3 x 10 = 30 Gy 3 x 11 = 33 Gy or 3 x 15 = 45 Gy (if 3 fractions) with the possibility of 3 x 20 Gy to the peripheral lung nodules with tracking in Cyberknife or 5 x 7 = 35 Gy or 5 Gy x 10 = 50 (if 5 fractions).
Beyond 3 cm of tumor diameter and / or to a distance of less than 1 cm from the GTV in an organ critical risk (eg spinal cord), a splitting up into 5 sessions must be privileged.
|
Stereotactic radiotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival without quality of life deterioration
Time Frame: 1 year
|
Overall Survival rate without definitive deterioration of quality of life (by QLQC30) measured at 1 year post treatment
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: 1 year
|
1 year
|
|
Progression free survival
Time Frame: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
|
Number of participants with adverse events grade 3 as assessed by CTCAE v4.0 within the first 6 months of treatment
Time Frame: up to 6 months
|
Toxicity of grade > or equal to 3, occurring within the first 6 months of treatment
|
up to 6 months
|
Number of participants with treatment related adverse events as assessed by CTCAE v4.0
Time Frame: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
|
Overall response rate
Time Frame: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GORTEC 2014-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Squamous Cell Carcinoma
-
Chase Heaton, MDIncyte Corporation; OncoSec Medical IncorporatedTerminatedRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell CarcinomaUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Advanced Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage IV Cutaneous...United States
-
Washington University School of MedicineActive, not recruitingSquamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Yonsei UniversityCompletedHead Neck Cancer Squamous Cell Recurrent | Head Neck Cancer Squamous Cell MetastaticKorea, Republic of
-
Washington University School of MedicineMerck Sharp & Dohme LLCActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Carcinoma, Squamous Cell of Head and Neck | Neoplasms, Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Eben RosenthalNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN)United States
-
Shanghai Ninth People's Hospital Affiliated to...RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell CarcinomaChina
-
University of PittsburghNational Cancer Institute (NCI)TerminatedSquamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma, Head And Neck | Carcinoma, Squamous Cell of Head and NeckUnited States
-
Xiang LuRecruitingHead and Neck Squamous Cell Carcinomas | Resectable Head and Neck Squamous-cell CarcinomaChina
-
Andrei IagaruNot yet recruitingHead-and-neck Squamous Cell CarcinomaUnited States
Clinical Trials on Chemotherapy
-
University of WashingtonNational Cancer Institute (NCI)CompletedAdult Acute Myeloid Leukemia | Adult Myelodysplastic SyndromeUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingColorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Colorectal Carcinoma Metastatic in the LungUnited States, Canada
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
International Atomic Energy AgencyCompletedNon Small Cell Lung CancerChile, China, Croatia, Egypt, India, Malaysia, Malta, Morocco, Pakistan, Panama, Peru, South Africa, Tunisia
-
Ping LiangNot yet recruitingChemotherapy | Liver Metastases | Colorectal Carcinoma
-
Second Affiliated Hospital, School of Medicine,...UnknownUnresectable Gastric Cancer | Successful Conversion Rate of OperationChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Yantai Yuhuangding HospitalRecruiting
-
Shenzhen SiBiono GeneTech Co.,LtdUnknown
-
Ruijin HospitalNot yet recruitingGastric Cancer | Neoadjuvant ChemotherapyChina